4.7 Review

Botulinum Neurotoxin Therapy in the Clinical Management of Laryngeal Dystonia

期刊

TOXINS
卷 14, 期 12, 页码 -

出版社

MDPI
DOI: 10.3390/toxins14120844

关键词

botulinum neurotoxin; laryngeal dystonia; spasmodic dysphonia; injection; electromyography

向作者/读者索取更多资源

Laryngeal dystonia is a chronic disorder affecting laryngeal movement, primarily interfering with phonation and speech, significantly diminishing patients' quality of life. Botulinum neurotoxin is the standard treatment for LD, with this article providing a comprehensive overview of its clinical application and therapeutic injection techniques in managing LD.
Laryngeal dystonia (LD), or spasmodic dysphonia (SD), is a chronic, task-specific, focal movement disorder affecting the larynx. It interferes primarily with the essential functions of phonation and speech. LD affects patients' ability to communicate effectively and significantly diminishes their quality of life. Botulinum neurotoxin was first used as a therapeutic agent in the treatment of LD four decades ago and remains the standard of care for the treatment of LD. This article provides an overview of the clinical application of botulinum neurotoxin in the management of LD, focusing on the classification for this disorder, its pathophysiology, clinical assessment and diagnosis, the role of laryngeal electromyography and a summary of therapeutic injection techniques, including a comprehensive description of various procedural approaches, recommendations for injection sites and dosage considerations.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据